Brain scan study hints at new way to tackle schizophrenia memory problems

NCT ID NCT04457310

Completed Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested whether a drug called CVL-562 can change brain activity related to working memory in people with early schizophrenia. 112 participants received different doses or a placebo while undergoing brain scans. The goal was to find brain imaging markers that could help develop better treatments for cognitive issues in schizophrenia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CVL-562 (PF-06412562)
What this could lead to: If successful, this study could help identify brain imaging markers that speed up development of new drugs for cognitive problems in schizophrenia.
What could go wrong: This is a small, early-phase study focused on measuring brain activity, not on proving the drug works. The results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY COURSE SCHIZOPHRENIA SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY COURSE SCHIZOPHRENIA SPECTRUM DISORDER

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Stony Brook University

Stony Brook, New York, 11794, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Yale University

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.